Increased hazard of death in community-tested cases of SARS-CoV-2 Variant of Concern 202012/01

Nicholas G. Davies[1][†], Christopher I. Jarvis[1], CMMID COVID-19 Working Group, W. John Edmunds[1], Nicholas P. Jewell[2,3], Karla Diaz-Ordaz[2,3]*, Ruth H. Keogh[2,3]*

1. Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK.
2. Department of Medical Statistics, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
3. Centre for Statistical Methodology, London School of Hygiene and Tropical Medicine, London, UK.

[†]Corresponding author. E-mail: nicholas.davies@lshtm.ac.uk
*Equal contribution

VOC 202012/01, a SARS-CoV-2 variant first detected in the United Kingdom in September
2020, has spread to multiple countries worldwide. Several studies have established that
this novel variant is more transmissible than preexisting variants, but have not identified
whether it leads to any change in disease severity. We analyse a large database of SARS-
CoV-2 community test results and COVID-19 deaths, representing 52% of all SARS-CoV-2
community tests in England from 1 September 2020 to 5 February 2021. This subset of
SARS-CoV-2 tests can identify VOC 202012/01 because mutations in this lineage prevent
PCR amplification of the spike gene target (S gene target failure, SGTF). We estimate that
the hazard of death among SGTF cases is 58% (95% CI 40–79%) higher than among non-
SGTF cases after adjustment for age, sex, ethnicity, deprivation level, care home
residence, local authority of residence and test date. This corresponds to the absolute
risk of death for a male aged 55–69 increasing from 0.6% to 0.9% (95% CI 0.8–1.0%) over
the 28 days following a positive test in the community. Correcting for misclassification of
SGTF and missingness in SGTF status, we estimate a 71% (48–97%) higher hazard of
death associated with VOC 202012/01. Our analysis suggests that VOC 202012/01 is not
only more transmissible than preexisting SARS-CoV-2 variants but may also cause more
severe illness.

Most community SARS-CoV-2 PCR tests in England are processed by one of six national
"Lighthouse" laboratories. Among the mutations carried by Variant of Concern (VOC) 202012/01
is a 6-nucleotide deletion which prevents amplification of the S gene target by the commercial
PCR assay used in three of the Lighthouse labs[1]. By linking individual records of positive
community tests with and without S gene target failure (SGTF) to a comprehensive line list of
COVID-19 deaths in England, we estimate the relative hazard of death associated with infection
by VOC 202012/01. We define confirmed SGTF as a compatible PCR result with cycle
threshold (Ct) < 30 for ORF1ab, Ct < 30 for N, and no detectable S (Ct > 40); confirmed non-
SGTF as any compatible PCR result with Ct < 30 for each of ORF1ab, N, and S; and an
inconclusive (missing) result as any other positive community test, including tests processed by
a laboratory incapable of assessing SGTF. We address missing SGTF status in our analysis.
49

50 ***Characteristics of the study population***
51

The study sample (**Table 1**) includes a total of 1,994,449individuals who had a positive
community ("Pillar 2") test between 1 November 2020 and 25 January 2021. Just over half of
those tested (1,028,296, 52%) had a conclusive SGTF reading and, of these, 48% had SGTF.
Females comprised 53.7% of the total sample; 44.4% were aged 1–34 years, 34.3% aged 35–
54, 15.1% aged 55–69, 4.3% aged 70–85 and 1.9% aged 85 or older. The majority of
individuals (93.7%) lived in residential accommodation (defined as residing in a house, flat,
sheltered accommodation, or house in multiple occupancy), with 3.1% living in a care or nursing
home. Based on self-identified ethnicity, 73.8% were White, 13.7% Asian, 4.7% Black and 7.8%
of other, mixed or unknown ethnicity. The data include tests performed in all 7 NHS England
regions, with the London region contributing 23.4% of tests and the South West 5.8%. The first
two weeks of the study period (1–14 Nov) contributed 12.6% of the total tests, and the final two
weeks (10–25 Jan) 22.2%. The period between 27 Dec and 9 Jan contributed 30.5% of tests.

In those with SGTF status measured, SGTF prevalence was similar in males and females but
lower in the older age groups: 54.9% in the 1-34 year olds compared with 48.6% in those aged
85 and older. In keeping with these age patterns, SGTF prevalence was lower in individuals
living in a care or nursing home (45.2%, compared to 54.7% among those in residential
accommodation). SGTF prevalence by self-identified ethnicity was 53.5% in the White group,
54.0% in the Asian group, 67.2% in the Black group, and 61.6% in the other, mixed, or unknown
ethnicity group. SGTF prevalence was lowest in the most deprived index of multiple deprivation[1]
(IMD) decile (43.9%) and highest in the least deprived decile (58.7%). The highest prevalences
of SGTF over the study period were observed in the East of England (75.7%), South East
(75.6%) and London (74.0%) NHS England regions, and prevalence of SGTF was lowest in the
North East and Yorkshire region (32.5%). The prevalence of SGTF also increased steeply over
time (**Fig. 1a**), ranging from 4.9% during 1–14 November 2020 to 87.4% during 10 –25 January
2021.

Having missing SGTF status was strongly associated with age and place of residence. The
proportion with SGTF status missing was similar in age groups 1-34 (47.9%), 35-54 (47.1%)
and 55-69 (47.7%), and then rose to 54.3% in the 70-84 age group and to 78.6% in the 85 and
older age group. SGTF status was missing in 89.1% of tests for individuals living in a care or
nursing home, compared to 46.9% of tests among individuals in residential accommodation.
This is partly due to more extensive use of lateral flow immunoassay tests in care homes, which
do not yield an SGTF reading. Missingness in SGTF status also differed substantially by NHS
England region, ranging from 21.5% in the North West to 70.8% in the South West. Missingness
also depended on specimen date, with the percentage missing being lower for the earlier
specimen dates and highest (55.4%) in the 2 week period that contributed the most tests (27
December-9 January). There were also some more minor differences in the percentages of
missingness of SGTF status by ethnicity and IMD. Of the 48% of tests with missing SGTF
status, 9% were inconclusive due to high Ct values and the remaining 39% were not analysed in
one of the three Lighthouse labs capable of producing an SGTF result.

The most commonly used definition of a COVID-19 death in England is any death occurring
within 28 days of a positive SARS-CoV-2 test. **Table 2** presents crude death rates within 28
days of a positive test per 10,000 person-days of follow-up. Death rates for unlimited follow-up
(i.e. not restricted to 28 days) are shown in Table S1; the maximum observed follow-up was 85
days. A total of 13,860 individuals out of the 1,994,449 in the study sample are known to have
died (0.69%), 12,967 of whom (92.8%) died within 28 days of their first positive test (**Fig. 1b**).
As expected, crude death rates were substantially higher in the elderly and in those living in a
care or nursing home.

Crude survival assessed by Kaplan-Meier curves was lower in the SGTF group (**Fig. 1c**).
Stratifying by broad age groups and looking at death rates by sex, place of residence, ethnicity,
IMD, NHS England region, and specimen date, it can be seen that death rates within 28 days of
a positive SARS-CoV-2 test are higher among SGTF than non-SGTF cases in 99 of the 108
strata assessed (92%; **Figs. 1d–i**).

Fig. 1. Descriptive analyses. a The number of samples with and without SGTF by day from 1 November 2020 to 25 January 2021, the period covered by our main analysis. **b** Number of deaths within 28 days of positive test by specimen date included in the analysis. **c** Kaplan-Meier plot showing survival among individuals tested in the community in England with and without SGTF, in the subset with SGTF measured. Inset shows the full *y*–axis range. **d–i** Crude death rates (with 95% confidence intervals) in SGTF and non-SGTF tests (in the subset with SGTF measured) for deaths within 28 days of positive test stratified by broad age groups and (**d**) sex, (**e**) place of residence, (**f**) ethnicity, (**g**) index of multiple deprivation, (**h**) NHS England region, and (**i**) specimen date. Dotted lines show the overall crude death rates by age group irrespective of SGTF status, with the shaded area showing the 95% CIs.

Cox regression analyses

To estimate the effect of SGTF on mortality while controlling for observed confounding, we fitted
a series of Cox proportional hazards models[2] to the data. We stratified the analysis by lower tier
local authority (LTLA) and specimen date to control for geographical and temporal differences in
the baseline hazard—for example, due to changes in hospital pressure during the study
period—and used spline terms for age and IMD and fixed effects for sex, ethnicity, and
residence type. All models were fitted twice, once using complete cases only, i.e. by simply
excluding individuals with missing SGTF status, and once using inverse probability weighting
(IPW), i.e. accounting for missingness by upweighting individuals whose characteristics—age,
sex, IMD, ethnicity, residence type, NHS England region of residence and sampling week—are
underrepresented among complete cases.

For the complete-cases analysis, the estimated hazard ratio for SGTF was 1.58 (95% CI 1.40–
1.79), indicating that the hazard of death within 28 days of a positive test is 58% (40–79%)
higher in those with SGTF compared to non-SGTF (**Fig. 2a**). We included an interaction term
between SGTF and time since positive test in the model to assess the proportional hazards
assumption. There was strong evidence of non-proportionality of hazards (likelihood ratio test
$P(\chi^2_1 = 7.1) = 0.008$; **Fig. 2a; Fig. S11**). The estimated time-varying hazard ratio increases
over time: 1.19 (0.94–1.52) one day after the positive test, 1.66 (1.46–1.88) on day 14, and 2.36
(1.71–3.25) on day 28. There was no evidence that adding higher-order functions of time into
the interaction terms improved model fit (likelihood ratio test $P(\chi^2_1 = 1.0) = 0.32$), and no
evidence of a significant interaction between time and age ($P(\chi^2_1 = 0.03) = 0.87$), time and
sex ($P(\chi^2_1 = 3.6) = 0.056$), time and IMD ($P(\chi^2_1 = 0.10) = 0.75$), time and ethnicity ($P(\chi^2_3 =$
$1.4) = 0.71$), or time and residence type ($P(\chi^2_2 = 1.5) = 0.47$).

We found no evidence of a significant interaction between SGTF and age group (likelihood ratio
test $P(\chi^2_4 = 6.7) = 0.15$), sex ($P(\chi^2_1 = 0.44) = 0.51$), IMD ($P(\chi^2_9 = 5.0) = 0.84$), or ethnicity
($P(\chi^2_3 = 0.95) = 0.81$). There was some evidence of an interaction between SGTF and
residence type ($P(\chi^2_2 = 6.8) = 0.034$), with the associated hazard ratio for SGTF being 1.53
(1.35–1.74) in standard residential accommodation , 2.43 (1.72–3.45) in care/nursing homes,
and 1.64 (0.80–3.38) in "other" residence types (i.e. residential institutions including residential
education, prisons and detention centres, medical facilities, no fixed abode and other/unknown).

In the investigation of a model for the probability of missingness in SGTF status, the cauchit
model was found to provide a good fit and to result in less extreme weights than the logistic
model. The IPW analysis was therefore performed using weights derived from the cauchit
model. The IPW analysis yielded similar results to the complete-cases analysis, generally with
marginally higher hazard ratios and wider CIs (**Fig. 2e**); the hazard ratio associated with SGTF
for the IPW analysis was 1.67 (1.46–1.90). While the IPW analysis recovered a similarly time-
varying hazard ratio to the complete-cases analysis, the increase was less marked (**Fig. 2c**) and
the inclusion of a time-varying term did not significantly improve model fit (Wald test $P(\chi^2_1 =$
$1.0) = 0.33$).

Fig. 2. Survival analyses. a–d Estimated hazard ratio of death within 28 days of positive test for (**a**)
SGTF, complete-cases analysis; (**b**) p_{VOC}, complete-cases analysis; (**c**) SGTF, IPW analysis; and (**d**)
p_{VOC}, IPW analysis, in model stratified by LTLA and specimen date and adjusted for the other covariates.
e Estimated hazard ratio of death within 28 days of positive test across each model investigated. Death
types are coded as follows: dX, all deaths within X days of a positive test; c28, death-certificate-confirmed
COVID-19 deaths within 28 days; e60, all deaths within 60 days plus all death-certificate-confirmed
COVID-19 deaths within any time period. S, spline term (for Age or IMD); L, linear term (for Age or IMD);
LTLA, lower-tier local authority (n = 316); UTLA, upper-tier local authority (n = 150); NHSE, NHS England
region (n = 7). LTLA start date signifies a start date chosen separately for each LTLA (see Methods).
Point estimates and 95% confidence intervals shown.

Misclassification analysis

Prior to the emergence of VOC 202012/01, a number of minor circulating SARS-CoV-2 lineages
with spike mutations could also cause SGTF[3]. Our main analyses are restricted to specimens
from 1 November 2020 onwards to minimise the number of these non-VOC 202012/01 lineages
among SGTF-positive samples. However, the appearance of non-VOC 202012/01 samples in
SGTF may dilute the estimated effect of VOC 202012/01 on the hazard of mortality. We
therefore undertook a misclassification analysis[4], modelling the relative frequency of SGTF over
time for each NHS England region as a combination of a low, time-invariant frequency of non-
VOC 202012/01 samples with SGTF plus a logistically growing[5] frequency of VOC 202012/01
samples with SGTF, which allows us to assign to each SGTF sample a probability p_{VOC} that the
sample is VOC 202012/01 based upon its specimen date and NHS England region (**Fig. S9**).
Again restricting the analysis to specimens from 1 November 2020 onward, we find a hazard
ratio associated with p_{VOC} of 1.63 (1.44–1.86) for the complete-cases analysis and 1.71 (1.48–
1.97) for the IPW analysis.

Absolute risks

To put these results into context, we estimated how the absolute risk of death due to COVID-19
may differ had an individual been infected with VOC 202012/01 compared with had they been
infected with the original variant. We calculated absolute risks by applying 28--day hazard ratios
for SGTF to the baseline risk of death estimated among individuals tested in the community
between August–October 2020 (expected to be representative of the CFR associated with
preexisting variants of SARS-CoV-2; **Table 3**). The risk of death due to COVID-19 following a
positive test in the community remains below 1% in most individuals younger than 70 years old.
For the complete cases analysis, in females aged 70–84, the estimated risk of death within 28
days of a positive SARS-CoV-2 test with SGTF increases from 2.9% to 4.5% (95% CI 4.0–
5.1%) and for females 85 or older increases from 13% to 20% (17–22%). For males aged 70–84
the risk of death within 28 days increases from 4.7% to 7.3% (6.4–8.2%) and for males 85 or
older it increases from 17% to 26% (23–28%). Estimates based on the IPW analysis were
marginally higher. These estimates reflect a substantial increase in absolute risk amongst older
age groups. Note that these estimates do not reflect the infection fatality ratio, but the fatality
ratio among people tested in the community, and are thus likely to be higher than the infection
fatality rate as many infected individuals will not have been tested.

Further investigations

We conducted a number of sensitivity analyses to verify the robustness of our results. Our main
results were largely insensitive to: restriction to death-certificate-confirmed COVID-19 deaths
only; any follow-up time of 21 days or longer; coarseness of geographical and temporal
stratification; use of linear versus spline terms for age and IMD; analysis start date; followup
time–covariate interactions; removal of the 10-day death registration cutoff; and restriction of the
analysis to individuals with a full 28-day follow-up period (**Fig. 2e**; **Table S2**). Pillar 2 testing
data include an indicator for whether the subject was tested because of symptoms or due to

asymptomatic screening. Although symptomatic status may lie on the causal pathway between
SGTF status and death, we adjusted for symptomatic status as a further sensitivity analysis and
found that it had no effect on the relative hazard of SGTF (1.58 [1.39–1.79], complete-cases
analysis).

Discussion
217
218
Our analysis identifies an increased hazard of death associated with VOC 202012/01 infection
relative to infection by preexisting SARS-CoV-2 variants. We controlled for several factors that
we hypothesised could confound the association between VOC 202012/01 infection status and
mortality. By controlling for test time and geographical location, via stratified analysis, mimicking
matching on these variables, we aimed to account for the fact that VOC 202012/01 infection
increased rapidly over time and differed substantially by region, and also that the hospitals in
which some individuals will have required care were subject to pressure on health services that
changed over time and by region.
227
We do not attempt to identify the mechanism for an increased mortality rate in this analysis.
There is some evidence that infections with VOC 202012/01 may be associated with higher viral
loads, as measured by Ct values detected during PCR testing of specimens (**Fig. S10**). Higher
viral loads resulting from infection with VOC 202012/01 may be partly responsible for the
observed increase in mortality, partly because they may reduce the efficacy of standard antiviral
treatments for COVID-19. The impact of viral load on observed SGTF mortality could be
assessed using a mediation analysis, which is outside the remit of this study.
235
Another potential explanation for an increased mortality rate among individuals testing positive
for VOC 202012/01 may be that this variant leads to changes in testing behaviour. If individuals
infected with this variant are less likely to show symptoms, then only relatively more severe
cases may get tested, and consequently our study would overestimate the infection fatality rate.
However, comparison to random population testing carried out by the Office for National
Statistics suggests no clear difference in the proportion of SGTF among Pillar 2 tests relative to
the population at large (**Fig. S12**).
243
We previously identified that the novel SARS-CoV-2 lineage VOC 202012/01 appears to have a
substantially greater transmission rate than preexisting variants of SARS-CoV-2[5], but could not
robustly estimate any increase or decrease in associated disease severity from ecological
analysis. The individual-level linked community testing data analysed here suggest that the
fatality rate among individuals infected with VOC 202012/01 is higher than that associated with
infection by preexisting variants. Crucially, due to the nature of the data currently available, we
were only able to assess mortality among individuals who received a positive test for SARS-
CoV-2 in the community. Indicators for VOC 202012/01 are not currently available for the vast
majority of individuals who die due to COVID-19, as they are first tested in hospital. Accordingly,
the evidence we provide here must be contextualised with further study of a larger population
sample, and in other settings. Nonetheless, by focusing on individuals tested in the community,
our analysis captures any combined effect of an altered risk of hospitalisation given positive test

and an altered risk of death given hospitalisation, which would not be fully captured by a study
focusing on hospitalised patients only.
258
Our findings are consistent with those identified by other groups using different methods to
verify the increased risk of death among community-tested individuals with SGTF[6]. Estimates of
increased mortality based upon Pillar 2 data will become more robust as test results and
mortality outcomes continue to accumulate over time. However, our approach of comparing
outcomes between individuals with and without SGTF who were tested in the same place and at
the same time would no longer accrue additional information at the point when SGTF becomes
effectively fixed in England, which may occur as soon as February 2021 if current trends
continue[5].
267
268

270
271

Methods

Data sources — We linked three datasets provided by Public Health England: a line list of all positive tests in England's "Pillar 2" (community) testing for SARS-CoV-2, containing specimen date and demographic information on the test subject; a line list of cycle threshold (Ct) values for the ORF1ab, N (nucleocapsid), and S (spike) genes for positive tests that were processed in one of the three national laboratories (Alderley Park, Glasgow, or Milton Keynes) utilising the Thermo Fisher TaqPath COVID-19 assay; and a line list of all deaths due to COVID-19 in England, which combines and deduplicates deaths reported by hospitals in England, by the Office for National Statistics, via direct reporting from Public Health England Health Protection Team, and via Demographic Batch Service tracing of laboratory-confirmed cases [7]. We link these datasets using a numeric identifier for Pillar 2 tests ('FINALID') common to all three datasets. We define S gene target failure (SGTF) as any test with Ct < 30 for ORF1ab and N targets but no detectable S gene, and non-SGTF as any test with Ct < 30 for ORF1ab, N, and S targets. A small proportion (9%) of SGTF tests are inconclusive. The study population of interest is defined as all individuals who received a positive Pillar 2 test between 1 November 2020 and 25 January 2021. For our main analysis, we included only tests from after 1 November 2020 to avoid including an excess of tests with SGTF not resulting from infection by VOC 202012/01. In sensitivity analyses, we also consider extending the population to include tests performed between 1 September and 31 October 2020..

The linked dataset available for analysis excludes individuals who first tested positive in hospital, that is, those who presented to hospital after symptom onset without first being tested in the community. This is because cycle threshold values used to ascertain SGTF status are not available for individuals who were not tested in the community. Our study sample comprises all community tests between 1 November 2020 and 25 January 2021, but only 7% of the total number of COVID-19 deaths were recorded within 28 days following a positive test in either the community or in hospital during this period. This is explained by differing mortality rates among individuals who first test positive in a hospital compared to those who first receive a community test.

There was a small amount of missing data for sex (n = 13, <0.01%), age (n = 151, <0.01%), and IMD and regional covariates (n = 3,428, 0.15%). There were no missing specimen dates. Individuals with missing age, sex, or geographical location were excluded. We also excluded individuals from the dataset whose age was recorded as zero, as there were 16,936 age-0 individuals compared to 8,867 age-1 individuals in the dataset, suggesting that many of these age-0 individuals may have been miscoded. There was some missing data on ethnicity (n = 43,032, 2%) and we created a category that combines missing values with "Other" and "Mixed". Missing values for residence type (n = 67,458, 3%) were also combined with an "Other" category. The data set used for the main analysis comprises 1,994,449 individuals, and SGTF status is missing for 966,153 (48%). In addition, the SGTF status of 97,461 individuals (9%) with an inconclusive SGTF test was set to missing. Missing data on the exposure is addressed in the analysis, described below.

We grouped residence types into three categories: Residential, which included the "Residential
dwelling (including houses, flats, sheltered accommodation)" and "House in multiple occupancy
(HMO)" groups; Care/Nursing home; and Other/Unknown, which included the "Medical facilities
(including hospitals and hospices, and mental health)", "No fixed abode", "Other property
classifications", "Overseas address", "Prisons, detention centres, secure units", "Residential
institution (including residential education)", and "Undetermined" groups, as well as unspecified
residence type. We grouped ethnicities into four categories according to the broad categories
used in the 2011 UK Census: Asian, which included the "Bangladeshi (Asian or Asian British)",
"Chinese (other ethnic group)", "Indian (Asian or Asian British)", "Pakistani (Asian or Asian
British)", and "Any other Asian background" groups; Black, which included the "African (Black or
Black British)", "Caribbean (Black or Black British)", and "Any other Black background" groups;
White, which included the "British (White)", "Irish (White)", and "Any other White background"
groups; and Other / Mixed / Unknown, which included the "Any other ethnic group", "White and
Asian (Mixed)", "White and Black African (Mixed)", "White and Black Caribbean (Mixed)", "Any
other Mixed background", and "Unknown" groups.
331
Statistical methods — There are several factors that we expect to be associated with both
SGTF and with risk of death, thus confounding the association between SGTF and risk of death
in those tested. Area of residence and specimen date were expected to be potentially strong
confounders. Area of residence is expected to be strongly associated with SGTF status due to
different virus variants circulating in different areas, and specimen date because the prevalence
of SGTF is known to have greatly increased over time. Area of residence and specimen date
are also expected to be associated with risk of death following a test, including due to
differential pressure on hospital resources by area and time. The following variables were also
identified as potential confounders: sex, age, place of residence (Residential, Care/Nursing
home, or Other/Unknown), ethnicity (White, Asian, Black, or Other/Mixed/Unknown), index of
multiple deprivation (IMD). The potential confounders are referred to collectively as the
covariates. For descriptive analyses, age (in years) was categorised as 1-34, 35-54, 55-69, 70-
84, 85 and older.
345
Descriptive analyses were performed. We tabulated the distribution of the covariates in the
whole study sample, and the association between each covariate and SGTF status in the
subset with SGTF measured (Table 1). We also summarised the association between each
covariate and missing data in SGTF status (Table 1). The subset with SGTF status measured
are referred to as the complete cases. The unadjusted association between SGTF and mortality
in the complete cases was assessed using a Kaplan-Meier plot (**Fig. 1c**) , and Kaplan-Meier
plots and crude mortality rates (**Table 2**) are also presented separately according to categories
of the covariates (**Figs. S1–S7**). Crude overall mortality rates were obtained for the whole
sample, by SGTF status in the complete cases, and and in those with missing SGTF status,
according to categories of each covariate (**Table 2**). We also obtained mortality rates by SGTF
status (in the complete cases) for categories of each covariate stratified by age group. Exact
Poisson CIs are used for mortality rates, assuming constant rate.
358

Approximately 46% of individuals in the study sample are missing data on SGTF status, due to
their test not being sent to one of the three laboratories utilising the Thermo Fisher TaqPath
COVID-19 assay or the test being inconclusive. We performed complete cases analysis,
restricted to the subset with SGTF status measured. This complete case analysis assumes that
for each analysis, the missing data, in this case missing SGTF status, is independent from the
outcome of interest, given the variables included in the models. This is a specific type of Missing
not at random assumption, as in particular it is allowed to depend on the underlying value of
SFTG. We also performed an analysis of the complete cases using inverse probability weights[8]
(IPW) to address the missing data on SGTF, under a missing at random assumption (MAR). In
the analysis, each individual with SGTF status measured is weighted by the inverse of their
probability of having SGTF status measured based on their covariates. For the IPW, the
missingness model estimated the probability of missingness using logistic regression with age
(restricted cubic spline), sex , IMD decile (restricted cubic spline), ethnicity , residence type ,
and NHS region by specimen week as predictors. We also considered a cauchit and a Gosset
link for the missingness model, including the same predictors, as this was expected to provide
better stability for the weights[9]. The fit of the missingness model was assessed using a Q-Q plot
(**Fig. S11**), and Hosmer-Lemeshow and Hinkley tests were used to choose the most appropriate
model.
377
Cox regression[2] was used to estimate the association between SGTF and the hazard for
mortality, conditioning on the potential confounders listed above. The analyses described here
were applied to the complete cases and using IPW, For IPW analyses, the standard errors
(SEs) accounted for the weights, though the fact that the weights were estimated was not
accounted for. This results in conservative SEs. The baseline hazard in the Cox model was
stratified by both specimen date and LTLA, therefore finely controlling for these variables. The
stratification gives a large number of strata matched by specimen date and LTLA. Only those
strata that contain individuals who die and individuals who survive contribute to the analysis.
The analysis is therefore similar to that which would be performed had we created a matched
nested case-control sample. The remaining variables were included as covariates in the model
(sex, age, place of residence, ethnicity, IMD decile). Age and IMD were included as restricted
cubic splines with 3 knots. The time origin for the analysis was specimen date and we
considered deaths up to 28 days after the specimen date. Individuals who did not die within 28
days were censored at the earlier of 28 days post specimen date and the administrative
censoring date, which we chose as the date of the most recent death linkable to SGTF status
minus 10 days (i.e., 25 January 2021) in order to minimise any potential bias due to late
reporting of deaths. We began by assuming proportionality of hazards for SGTF and the
covariates included in the model. The proportional hazards assumption was assessed by
including in the model an interaction between each covariate and time, which was performed
separately for SGTF and for each other covariate. Schoenfeld residual plots were also obtained
for each covariate (**Fig. S8**). We assessed whether the association between SGTF and the
hazard was modified by age, sex, IMD, ethnicity, and place of residence. Models with and
without interactions were compared using likelihood ratio tests for the complete cases analyses.
For the analysis using IPW we used Wald tests based on robust standard errors[10].
402

403   The analysis assumes that censoring is uninformative, which is plausible as all censoring is
404   administrative.
405
Misclassification analysis — The exposure of SGTF is subject to misclassification, because a
number of minor circulating variants of SARS-CoV-2 in addition to VOC 202012/01 are also
associated with failure to amplify the spike gene target. Accordingly, a positive test with SGTF is
not necessarily indicative of infection with VOC 202012/01. A negative test of SGTF is assumed
to be indicative of absence of infection with VOC 202012/01. Misclassification of an exposure
can result in bias in its estimated association with the outcome. We fitted a logistic model to
Pillar 2 SGTF frequencies by NHS region to estimate a "background" rate of SGTF in the
absence of VOC 202012/01, assuming a beta binomial prior. This model is then used to
estimate the probability that an individual testing positive with SGTF is infected with VOC
202012/01, separately for individuals in each NHS region. These probabilities can then be used
in place of the indicator of SGTF exposure in the Cox models. This is the regression calibration
approach[4] to correcting for bias due to measurement error in an exposure. .
418
419   We fitted models accounting for false positives (modelled as regionally-varying background
420   rates of SGTF associated with non-VOC 202012/01 variants) to the SGTF data. Our logistic
421   model for VOC 202012/01 growth over time is as follows:
422

$$logit\,(f(t)) = (slope \times (t - intercept))$$
$$s(t) = f(t) + (1 - f(t)) \times falsepos$$
$$k_t \sim betaBinomial(n = n_t, \alpha = s(t) \times (conc - 2) + 1, \beta = (1 - s(t)) \times (conc - 2) + 1)$$
$$slope \sim normal(\mu = 0, \sigma = 1)$$
$$intercept \sim normal(\mu = 0, \sigma = 1000)$$
$$falsepos \sim beta(\alpha = 1.5, \beta = 15)$$
$$conc \sim normal(\mu = 0, \sigma = 500) \geq 2$$

430
Here, *f(t)* is the predicted frequency of VOC 202012/01 among positive tests at time *t* (in days
since 1 September 2020) based on the terms *slope* and *intercept*; *s(t)* is the predicted frequency
of S gene target failure at time *t* due to the combination of VOC 202012/01 and a background
false positive rate *falsepos*, *conc* is the "concentration" parameter (= α + β) of a beta distribution
with mode *s(t)*; k_t is the number of S gene target failures detected at time *t*; and n_t is the total
number of tests at time *t*. All priors above are chosen to be vague, and the truncation of *conc* to
values greater than 2 ensures a unimodal distribution for the proportion of tests that are SGTF.
The model above is fitted separately for each NHS England region. Then, p_{VOC} for a test with
SGTF = 1 at time *t* is equal to $f(t)/s(t)$, and p_{VOC} = 0 for all tests with SGTF = 0.
440
The model above was fitted using the same data source (i.e. SGTF frequencies among Pillar 2
community tests for SARS-CoV-2) as our survival analysis. To verify the robustness of this
model, we performed a sensitivity analysis using sequencing data from the COVID-19 UK
Genomics Consortium[11] downloaded from the Microreact platform[12] on 11 January 2020 to
estimate p_{VOC}. In this alternative analysis we estimated p_{VOC} for each NHS England region and

date as the number of samples that were VOC 202012/01 (i.e. lineage B.1.1.7 with mutations

Δ69/Δ70 and N501Y in Spike) divided by the number of samples that were SGTF (i.e. any

lineage with Δ69/Δ70, the deletion that causes SGTF) for that NHS England region and date,

setting p_{VOC} = 1 for all dates later than 31 December 2020 as there were no sequencing data

available past this date, and filling any gaps in the data using linear interpolation. This yielded
nearly identical results to our modelled probability of VOC (**Fig. 2e**).

Absolute risks — Estimates from the final Cox models were used to obtain estimates of absolute
risk of death for 28 and 60 days with SGTF and p_{VOC}. Given the strong influence of age on risk
of death, we present absolute risks by sex and age group (1-34, 35-54, 55-69, 70-84, 85+).
Absolute risks of death (case fatality rate) within 28 and 60 days were estimated by age group
and sex using data on individuals tested during September 2020; this is referred to as the
baseline risk. The absolute risks of death for individuals with SGTF were then estimated as
follows. If the baseline absolute risk of death in a given age group is $(1 - A)$, then the estimated
absolute risk of death with SGTF is $(1 - A^{HR})$, where HR denotes the estimated hazard ratio
obtained from the Cox model assuming proportional hazards. We applied the hazard ratio from
28 days to the baseline risk for 28 days, and the hazard ratio for 60 days to the baseline risk for
60 days, to estimate absolute risks of death for individuals with SGTF and uncertainty of these
estimates. Standard errors are obtained via the delta method, and CIs based on normal
approximations.

Sensitivity analyses — Several sensitivity analyses were performed. After establishing the final
model through using the process outlined above we investigated the impact of using different
variables for stratification of the baseline hazard measuring region at a coarser level (UTLA, or
NHS England region), as well as coarser test specimen time (week rather than exact date).
Adjusting for these variables instead of using stratification was also explored. We also repeated
the main analysis restricting data to specimens collected from September onwards, October
onwards, November onwards, or December onwards.

To assess the impact of imposing an administrative cutoff to follow-up time of 10 days prior to
data extraction, we first reanalysed the data without this cutoff, as well as reanalysing the data
restricting the analysis to individuals with at least 28 days' follow-up.

Finally, we adjusted for symptomatic status associated withthe test (asymptomatic,
symptomatic, or unknown), which relates to whether the test was given for asymptomatic
screening purposes or on the basis of a request by a (presumed symptomatic) individual, as
only symptomatic individuals may request a community SARS-CoV-2 test in England.

Acknowledgements
We gratefully acknowledge the assistance of Public Health England in providing the analysis
data and authorising release of an anonymised data set.

Funding statement

NGD: UK Research and Innovation (UKRI) Research England; NIHR Health Protection
Research Unit in Immunisation (NIHR200929); UK Medical Research Council (MC_PC_19065).
CIJ: Global Challenges Research Fund project 'RECAP' managed through Research Councils
UK and the Economic and Social Research Council (ES/P010873/1). WJE: European
Commission (EpiPose 101003688), National Institutes of Health Research (NIHR200908). NPJ:
National Institutes of Health / National Institute of Allergy and Infectious Diseases
(R01AI148127). KDO: Royal Society-Wellcome Trust Sir Henry Dale Fellowship 218554/Z/19/Z.
RHK: UKRI Future Leaders Fellowship (MR/S017968/1).
494

Working group authors and acknowledgements

The CMMID COVID-19 working group is (randomized order) Kevin van Zandvoort, Samuel
Clifford, Fiona Yueqian Sun, Sebastian Funk, Graham Medley, Yalda Jafari, Sophie R Meakin,
Rachel Lowe, W John Edmunds, Matthew Quaife, Naomi R Waterlow, Rosalind M Eggo,
Nicholas G. Davies, Jiayao Lei, Mihaly Koltai, Fabienne Krauer, Damien C Tully, James D
Munday, Alicia Showering, Anna M Foss, Kiesha Prem, Stefan Flasche, Adam J Kucharski,
Sam Abbott, Billy J Quilty, Thibaut Jombart, Alicia Rosello, Gwenan M Knight, Mark Jit, Yang
Liu, Jack Williams, Joel Hellewell, Kathleen O'Reilly, Yung-Wai Desmond Chan, Timothy W
Russell, Christopher I Jarvis, Simon R Procter, Akira Endo, Emily S Nightingale, Nikos I Bosse ,
C Julian Villabona-Arenas, Frank G Sandmann, Amy Gimma, Kaja Abbas, William Waites,
Katherine E. Atkins, Rosanna C Barnard, Petra Klepac, Hamish P Gibbs, Carl A B Pearson, and
Oliver Brady.
507

Funding statements for the CMMID COVID-19 working group are as follows. KvZ: KvZ is
supported by the UK Foreign, Commonwealth and Development Office (FCDO)/Wellcome Trust
Epidemic Preparedness Coronavirus research programme (ref. 221303/Z/20/Z), and Elrha's
Research for Health in Humanitarian Crises (R2HC) Programme, which aims to improve health
outcomes by strengthening the evidence base for public health interventions in humanitarian
crises. The R2HC programme is funded by the UK Government (FCDO), the Wellcome Trust,
and the UK National Institute for Health Research (NIHR). SC: Wellcome Trust (grant:
208812/Z/17/Z). FYS: NIHR EPIC grant (16/137/109). SFunk: Wellcome Trust (grant:
210758/Z/18/Z), NIHR (NIHR200908). GFM: NTD Modelling Consortium by the Bill and Melinda
Gates Foundation (OPP1184344). YJ: LSHTM, DHSC/UKRI COVID-19 Rapid Response
Initiative. SRM: Wellcome Trust (grant: 210758/Z/18/Z). RL: Royal Society Dorothy Hodgkin
Fellowship. WJE: European Commission (EpiPose 101003688), NIHR (NIHR200908). MQ:
European Research Council Starting Grant (Action Number #757699); Bill and Melinda Gates
Foundation (INV-001754). NRW: Medical Research Council (grant number MR/N013638/1).
RME: HDR UK (grant: MR/S003975/1), MRC (grant: MC_PC 19065), NIHR (grant:
NIHR200908). NGD: UKRI Research England; NIHR Health Protection Research Unit in
Immunisation (NIHR200929); UK MRC (MC_PC_19065). JYL: Bill & Melinda Gates Foundation
(INV-003174). MK: Foreign, Commonwealth and Development Office / Wellcome Trust. FK:
Innovation Fund of the Joint Federal Committee (Grant number 01VSF18015), Wellcome Trust
(UNS110424). DCT: No funding declared. JDM: Wellcome Trust (grant: 210758/Z/18/Z). AS: No
funding declared. AMF: No funding declared. KP: Gates (INV-003174), European Commission
(101003688). SFlasche: Wellcome Trust (grant: 208812/Z/17/Z). AJK: Wellcome Trust (grant:

206250/Z/17/Z), NIHR (NIHR200908). SA: Wellcome Trust (grant: 210758/Z/18/Z). BJQ: This research was partly funded by the National Institute for Health Research (NIHR) (16/137/109 & 16/136/46) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care. BJQ is supported in part by a grant from the Bill and Melinda Gates Foundation (OPP1139859). TJ: RCUK/ESRC (grant: ES/P010873/1); UK PH RST; NIHR HPRU Modelling & Health Economics (NIHR200908). AR: NIHR (grant: PR-OD-1017-20002). GMK: UK Medical Research Council (grant: MR/P014658/1). MJ: Gates (INV-003174, INV-016832), NIHR (16/137/109, NIHR200929, NIHR200908), European Commission (EpiPose 101003688). YL: Gates (INV-003174), NIHR (16/137/109), European Commission (101003688). JW: NIHR Health Protection Research Unit and NIHR HTA. JH: Wellcome Trust (grant: 210758/Z/18/Z). KO'R: Bill and Melinda Gates Foundation (OPP1191821). YWDC: No funding declared. TWR: Wellcome Trust (grant: 206250/Z/17/Z). CIJ: Global Challenges Research Fund (GCRF) project 'RECAP' managed through RCUK and ESRC (ES/P010873/1). SRP: Bill and Melinda Gates Foundation (INV-016832). AE: The Nakajima Foundation. ESN: Gates (OPP1183986). NIB: Health Protection Research Unit (grant code NIHR200908). CJVA: European Research Council Starting Grant (Action number 757688). FGS: NIHR Health Protection Research Unit in Modelling & Health Economics, and in Immunisation. AG: European Commission (EpiPose 101003688). KA: Bill & Melinda Gates Foundation (OPP1157270, INV-016832). WW: MRC (grant MR/V027956/1). KEA: European Research Council Starting Grant (Action number 757688). RCB: European Commission (EpiPose 101003688). PK: This research was partly funded by the Royal Society under award RP\EA\180004, European Commission (101003688), Bill & Melinda Gates Foundation (INV-003174). HPG: This research was produced by CSIGN which is part of the EDCTP2 programme supported by the European Union (grant number RIA2020EF-2983-CSIGN). The views and opinions of authors expressed herein do not necessarily state or reflect those of EDCTP. This research is funded by the Department of Health and Social Care using UK Aid funding and is managed by the NIHR. The views expressed in this publication are those of the author(s) and not necessarily those of the Department of Health and SocialCare (PR-OD-1017-20001). CABP: CABP is supported by the Bill & Melinda Gates Foundation (OPP1184344) and the UK Foreign, Commonwealth and Development Office (FCDO)/Wellcome Trust Epidemic Preparedness Coronavirus research programme (ref. 221303/Z/20/Z). OJB: Wellcome Trust (grant: 206471/Z/17/Z).

Ethical approval

Approved by the Observational / Interventions Research Ethics Committee at the London School of Hygiene and Tropical Medicine (reference number 24020). Subject consent is not required for national infectious disease notification data sets in England.

Code and data availability

Analysis code is available at https://github.com/nicholasdavies/cfrvoc. An anonymised data set allowing replication of the analysis is available at the same URL.

573   **Tables**
574
575   **Table 1. Characteristics of study subjects, 1 November 2020–25 January 2021.**
576

	All N(%)	Missing N(%)	SGTF N(%) In subset with SGTF status measured	Non-SGTF N(%) In subset with SGTF status measured	SGTF prevalence N with SGTF/Total (%), in subset with SGTF status measured	Missingness N with missing SGTF status/Total (%)
	1,994,449 (100%)	966,153 (100%)	562,282 (100%)	466,014 (100%)	562,282 / 1,028,296 (54.7%)	966,153 / 1,994,449 (48.4%)
Sex						
Female	1,071,783 (53.7%)	533,309 (55.2%)	291,479 (51.8%)	246,995 (53%)	291,479 / 538,474 (54.1%)	533,309 / 1,071,783 (49.8%)
Male	922,666 (46.3%)	432,844 (44.8%)	270,803 (48.2%)	219,019 (47%)	270,803 / 489,822 (55.3%)	432,844 / 922,666 (46.9%)
Age in years						
1–34	886,034 (44.4%)	424,034 (43.9%)	253,832 (45.1%)	208,168 (44.7%)	253,832 / 462,000 (54.9%)	424,034 / 886,034 (47.9%)
35–54	684,762 (34.3%)	322,780 (33.4%)	201,019 (35.8%)	160,963 (34.5%)	201,019 / 361,982 (55.5%)	322,780 / 684,762 (47.1%)
55–69	300,329 (15.1%)	143,368 (14.8%)	84,213 (15%)	72,748 (15.6%)	84,213 / 156,961 (53.7%)	143,368 / 300,329 (47.7%)
70–84	86,320 (4.3%)	46,885 (4.9%)	19,372 (3.4%)	20,063 (4.3%)	19,372 / 39,435 (49.1%)	46,885 / 86,320 (54.3%)
85 and older	37,004 (1.9%)	29,086 (3%)	3,846 (0.7%)	4,072 (0.9%)	3,846 / 7,918 (48.6%)	29,086 / 37,004 (78.6%)
Place of residence						
Residential	1,868,902 (93.7%)	876,831 (90.8%)	542,875 (96.5%)	449,196 (96.4%)	542,875 / 992,071 (54.7%)	876,831 / 1,868,902 (46.9%)
Care/Nursing home	61,380 (3.1%)	54,681 (5.7%)	3,027 (0.5%)	3,672 (0.8%)	3,027 / 6,699 (45.2%)	54,681 / 61,380 (89.1%)
Other/Unknown	64,167 (3.2%)	34,641 (3.6%)	16,380 (2.9%)	13,146 (2.8%)	16,380 / 29,526 (55.5%)	34,641 / 64,167 (54%)
Ethnicity						
White	1,471,201 (73.8%)	704,038 (72.9%)	410,447 (73%)	356,716 (76.5%)	410,447 / 767,163 (53.5%)	704,038 / 1,471,201 (47.9%)
Asian	273,184 (13.7%)	124,762 (12.9%)	80,133 (14.3%)	68,289 (14.7%)	80,133 / 148,422 (54%)	124,762 / 273,184 (45.7%)

Black	93,848 (4.7%)	52,970 (5.5%)	27,480 (4.9%)	13,398 (2.9%)	27,480 / 40,878 (67.2%)	52,970 / 93,848 (56.4%)
Other/Mixed/Unknown	156,216 (7.8%)	84,383 (8.7%)	44,222 (7.9%)	27,611 (5.9%)	44,222 / 71,833 (61.6%)	84,383 / 156,216 (54%)
Index of Multiple Deprivation decile						
1	205,863 (10.3%)	75,437 (7.8%)	57,280 (10.2%)	73,146 (15.7%)	57,280 / 130,426 (43.9%)	75,437 / 205,863 (36.6%)
2	238,287 (11.9%)	113,291 (11.7%)	65,777 (11.7%)	59,219 (12.7%)	65,777 / 124,996 (52.6%)	113,291 / 238,287 (47.5%)
3	240,562 (12.1%)	119,894 (12.4%)	67,143 (11.9%)	53,525 (11.5%)	67,143 / 120,668 (55.6%)	119,894 / 240,562 (49.8%)
4	221,232 (11.1%)	111,768 (11.6%)	62,722 (11.2%)	46,742 (10%)	62,722 / 109,464 (57.3%)	111,768 / 221,232 (50.5%)
5	206,211 (10.3%)	105,116 (10.9%)	58,259 (10.4%)	42,836 (9.2%)	58,259 / 101,095 (57.6%)	105,116 / 206,211 (51%)
6	194,183 (9.7%)	99,921 (10.3%)	54,158 (9.6%)	40,104 (8.6%)	54,158 / 94,262 (57.5%)	99,921 / 194,183 (51.5%)
7	184,217 (9.2%)	92,220 (9.5%)	51,572 (9.2%)	40,425 (8.7%)	51,572 / 91,997 (56.1%)	92,220 / 184,217 (50.1%)
8	179,610 (9%)	88,611 (9.2%)	50,386 (9%)	40,613 (8.7%)	50,386 / 90,999 (55.4%)	88,611 / 179,610 (49.3%)
9	172,325 (8.6%)	85,417 (8.8%)	49,511 (8.8%)	37,397 (8%)	49,511 / 86,908 (57%)	85,417 / 172,325 (49.6%)
10	151,959 (7.6%)	74,478 (7.7%)	45,474 (8.1%)	32,007 (6.9%)	45,474 / 77,481 (58.7%)	74,478 / 151,959 (49%)
NHS England region						
East of England	250,910 (12.6%)	160,554 (16.6%)	68,444 (12.2%)	21,912 (4.7%)	68,444 / 90,356 (75.7%)	160,554 / 250,910 (64%)
London	467,366 (23.4%)	278,708 (28.8%)	139,622 (24.8%)	49,036 (10.5%)	139,622 / 188,658 (74%)	278,708 / 467,366 (59.6%)
Midlands	364,764 (18.3%)	161,896 (16.8%)	90,121 (16%)	112,747 (24.2%)	90,121 / 202,868 (44.4%)	161,896 / 364,764 (44.4%)
North East and Yorkshire	240,130 (12%)	53,697 (5.6%)	60,552 (10.8%)	125,881 (27%)	60,552 / 186,433 (32.5%)	53,697 / 240,130 (22.4%)
North West	231,160 (11.6%)	49,691 (5.1%)	77,642 (13.8%)	103,827 (22.3%)	77,642 / 181,469 (42.8%)	49,691 / 231,160 (21.5%)
South East	324,067 (16.2%)	179,493 (18.6%)	109,297 (19.4%)	35,277 (7.6%)	109,297 / 144,574 (75.6%)	179,493 / 324,067 (55.4%)

South West	116,052 (5.8%)	82,114 (8.5%)	16,604 (3%)	17,334 (3.7%)	16,604 / 33,938 (48.9%)	82,114 / 116,052 (70.8%)
Specimen date						
1 Nov–14 Nov	251,389 (12.6%)	86,954 (9%)	8,027 (1.4%)	156,408 (33.6%)	8,027 / 164,435 (4.9%)	86,954 / 251,389 (34.6%)
15 Nov–28 Nov	168,861 (8.5%)	57,694 (6%)	12,236 (2.2%)	98,931 (21.2%)	12,236 / 111,167 (11%)	57,694 / 168,861 (34.2%)
29 Nov–12 Dec	166,423 (8.3%)	61,600 (6.4%)	37,890 (6.7%)	66,933 (14.4%)	37,890 / 104,823 (36.1%)	61,600 / 166,423 (37%)
13 Dec–26 Dec	356,259 (17.9%)	186,943 (19.3%)	111,237 (19.8%)	58,079 (12.5%)	111,237 / 169,316 (65.7%)	186,943 / 356,259 (52.5%)
27 Dec–9 Jan	607,884 (30.5%)	336,667 (34.8%)	211,717 (37.7%)	59,500 (12.8%)	211,717 / 271,217 (78.1%)	336,667 / 607,884 (55.4%)
10 Jan–25 Jan	443,633 (22.2%)	236,295 (24.5%)	181,175 (32.2%)	26,163 (5.6%)	181,175 / 207,338 (87.4%)	236,295 / 443,633 (53.3%)

577
578

579 **Table 2. Rates of death within 28 days of positive test among study subjects.** Total
580 number of deaths, number of days of followup, and deaths per 10,000 days of followup
581 reported.
582

	All	Missing SGTF status	SGTF	Non-SGTF
	12,790 / 43,774,085 (2.92)	9,408 / 20,572,452 (4.57)	1,722 / 10,961,652 (1.57)	1,660 / 12,239,982 (1.36)
Sex				
Female	6,733 / 23,564,628 (2.86)	5,293 / 11,396,647 (4.64)	714 / 5,682,724 (1.26)	726 / 6,485,256 (1.12)
Male	6,057 / 20,209,458 (3)	4,115 / 9,175,804 (4.48)	1,008 / 5,278,928 (1.91)	934 / 5,754,726 (1.62)
Age				
1–34	50 / 19,706,054 (0.03)	20 / 9,177,761 (0.02)	16 / 5,026,025 (0.03)	14 / 5,502,268 (0.03)
35–54	512 / 15,077,156 (0.34)	244 / 6,891,346 (0.35)	165 / 3,947,176 (0.42)	103 / 4,238,634 (0.24)
55–69	1,533 / 6,490,368 (2.36)	775 / 3,011,166 (2.57)	454 / 1,583,118 (2.87)	304 / 1,896,083 (1.6)
70–84	4,364 / 1,818,684 (24)	3,025 / 956,804 (31.62)	656 / 351,155 (18.68)	683 / 510,724 (13.37)
85 and older	6,331 / 681,824 (92.85)	5,344 / 535,374 (99.82)	431 / 54,177 (79.55)	556 / 92,272 (60.26)
Place of residence				
Residential	4,890 / 41,205,718 (1.19)	2,271 / 18,777,676 (1.21)	1,422 / 10,615,334 (1.34)	1,197 / 11,812,709 (1.01)
Care/Nursing home	7,664 / 1,202,997 (63.71)	6,941 / 1,081,248 (64.19)	279 / 39,006 (71.53)	444 / 82,744 (53.66)
Other/Unknown	236 / 1,365,370 (1.73)	196 / 713,528 (2.75)	21 / 307,312 (0.68)	19 / 344,530 (0.55)
Ethnicity				
White	11,340 / 32,415,402 (3.5)	8,557 / 15,118,520 (5.66)	1,370 / 7,959,838 (1.72)	1,413 / 9,337,044 (1.51)
Asian	887 / 6,020,388 (1.47)	472 / 2,630,158 (1.79)	236 / 1,569,368 (1.5)	179 / 1,820,862 (0.98)
Black	227 / 1,960,509 (1.16)	137 / 1,065,071 (1.29)	63 / 544,514 (1.16)	27 / 350,924 (0.77)
Other/Mixed/Unknown	336 / 3,377,786 (0.99)	242 / 1,758,702 (1.38)	53 / 887,932 (0.6)	41 / 731,152 (0.56)
Index of Multiple Deprivation decile				

1	1,211 / 4,415,279 (2.74)	666 / 1,572,214 (4.24)	223 / 949,311 (2.35)	322 / 1,893,754 (1.7)
2	1,284 / 5,142,166 (2.5)	848 / 2,362,174 (3.59)	213 / 1,229,998 (1.73)	223 / 1,549,994 (1.44)
3	1,266 / 5,223,651 (2.42)	886 / 2,522,071 (3.51)	177 / 1,295,302 (1.37)	203 / 1,406,278 (1.44)
4	1,381 / 4,793,728 (2.88)	1,034 / 2,348,872 (4.4)	197 / 1,217,608 (1.62)	150 / 1,227,248 (1.22)
5	1,341 / 4,515,820 (2.97)	1,060 / 2,227,180 (4.76)	160 / 1,159,819 (1.38)	121 / 1,128,821 (1.07)
6	1,346 / 4,257,826 (3.16)	1,025 / 2,122,558 (4.83)	182 / 1,079,483 (1.69)	139 / 1,055,786 (1.32)
7	1,256 / 4,088,424 (3.07)	995 / 1,988,609 (5)	141 / 1,033,880 (1.36)	120 / 1,065,936 (1.13)
8	1,284 / 4,006,295 (3.2)	991 / 1,921,732 (5.16)	161 / 1,014,684 (1.59)	132 / 1,069,878 (1.23)
9	1,308 / 3,878,992 (3.37)	1,045 / 1,864,794 (5.6)	132 / 1,023,407 (1.29)	131 / 990,790 (1.32)
10	1,113 / 3,451,904 (3.22)	858 / 1,642,247 (5.22)	136 / 958,161 (1.42)	119 / 851,496 (1.4)
NHS England region				
East of England	1,783 / 5,511,951 (3.23)	1,527 / 3,471,280 (4.4)	183 / 1,455,449 (1.26)	73 / 585,222 (1.25)
London	1,426 / 10,377,194 (1.37)	1,073 / 5,914,652 (1.81)	281 / 3,127,714 (0.9)	72 / 1,334,828 (0.54)
Midlands	2,615 / 7,840,529 (3.34)	1,868 / 3,284,336 (5.69)	326 / 1,575,152 (2.07)	421 / 2,981,042 (1.41)
North East and Yorkshire	1,729 / 5,542,494 (3.12)	858 / 1,228,923 (6.98)	271 / 1,000,771 (2.71)	600 / 3,312,800 (1.81)
North West	1,318 / 4,904,162 (2.69)	713 / 1,116,972 (6.38)	259 / 1,157,800 (2.24)	346 / 2,629,389 (1.32)
South East	2,801 / 7,142,670 (3.92)	2,391 / 3,859,346 (6.2)	336 / 2,341,873 (1.43)	74 / 941,450 (0.79)
South West	1,118 / 2,455,085 (4.55)	978 / 1,696,942 (5.76)	66 / 302,894 (2.18)	74 / 455,250 (1.63)
Specimen date				
1 Nov–14 Nov	1,449 / 7,017,250 (2.06)	907 / 2,420,610 (3.75)	20 / 224,495 (0.89)	522 / 4,372,145 (1.19)
15 Nov–28 Nov	1,257 / 4,708,381 (2.67)	922 / 1,600,898 (5.76)	25 / 342,278 (0.73)	310 / 2,765,204 (1.12)

29 Nov–12 Dec	1,402 / 4,638,356 (3.02)	1,013 / 1,708,928 (5.93)	124 / 1,059,364 (1.17)	265 / 1,870,064 (1.42)
13 Dec–26 Dec	2,078 / 9,944,324 (2.09)	1,514 / 5,211,339 (2.91)	349 / 3,110,010 (1.12)	215 / 1,622,976 (1.32)
27 Dec–9 Jan	4,706 / 13,706,868 (3.43)	3,636 / 7,635,678 (4.76)	814 / 4,709,516 (1.73)	256 / 1,361,674 (1.88)
10 Jan–25 Jan	1,898 / 3,758,906 (5.05)	1,416 / 1,994,996 (7.1)	390 / 1,515,990 (2.57)	92 / 247,919 (3.71)

583
584

585 **Table 3. Absolute 28-day mortality risk associated with SGTF, as expressed by case**
586 **fatality ratio (%) among individuals testing positive in the community.** The baseline (i.e.
587 original variant) absolute risk after 28 days post-test is derived using linked deaths for all
588 individuals testing positive in the community from 1 August – 31 October 2020. Results
589 presented for both complete cases and IPW analysis.
590

Sex	Age	Baseline CFR	Variant CFR (complete cases)	Variant CFR (IPW)
Female	0-34	0.00069%	0.0011% (0.00096-0.0012)	0.0012% (0.001-0.0013)
Female	35-54	0.033%	0.052% (0.045-0.058)	0.054% (0.047-0.062)
Female	55-69	0.18%	0.29% (0.25-0.32)	0.3% (0.26-0.34)
Female	70-84	2.9%	4.5% (4-5.1)	4.7% (4.1-5.4)
Female	85 and older	13%	20% (17-22)	20% (18-23)
Male	0-34	0.0031%	0.0048% (0.0042-0.0055)	0.0051% (0.0044-0.0058)
Male	35-54	0.063%	0.099% (0.087-0.11)	0.1% (0.09-0.12)
Male	55-69	0.56%	0.88% (0.77-0.99)	0.93% (0.8-1)
Male	70-84	4.7%	7.3% (6.4-8.2)	7.6% (6.7-8.6)
Male	85 and older	17%	26% (23-28)	27% (24-30)

591
592

593 **Supplementary tables**
594
595 **Table S1. Rates of death within any time period following positive test among study**
596 **subjects, including missing SGTF status.** Total number of deaths, number of days of
597 followup, and deaths per 10,000 days of followup reported.
598

	All	Missing	SGTF	Non-SGTF
	13,860 / 69,160,118 (2)	10,127 / 29,806,446 (3.4)	1,785 / 13,504,310 (1.32)	1,948 / 25,849,361 (0.75)
Sex				
Female	7,314 / 37,253,988 (1.96)	5,729 / 16,563,712 (3.46)	734 / 7,008,795 (1.05)	851 / 13,681,482 (0.62)
Male	6,546 / 31,906,130 (2.05)	4,398 / 13,242,734 (3.32)	1,051 / 6,495,516 (1.62)	1,097 / 12,167,880 (0.9)
Age				
1–34	55 / 31,260,216 (0.02)	20 / 13,348,169 (0.01)	16 / 6,266,754 (0.03)	19 / 11,645,294 (0.02)
35–54	570 / 23,686,455 (0.24)	262 / 9,887,338 (0.26)	176 / 4,861,304 (0.36)	132 / 8,937,812 (0.15)
55–69	1,712 / 10,271,464 (1.67)	838 / 4,359,417 (1.92)	480 / 1,898,842 (2.53)	394 / 4,013,205 (0.98)
70–84	4,724 / 2,899,684 (16.29)	3,269 / 1,410,603 (23.17)	673 / 415,546 (16.2)	782 / 1,073,534 (7.28)
85 and older	6,799 / 1,042,298 (65.23)	5,738 / 800,919 (71.64)	440 / 61,864 (71.12)	621 / 179,516 (34.59)
Place of residence				
Residential	5,344 / 64,971,901 (0.82)	2,429 / 26,956,788 (0.9)	1,475 / 13,075,518 (1.13)	1,440 / 24,939,596 (0.58)
Care/Nursing home	8,271 / 2,010,503 (41.14)	7,495 / 1,800,672 (41.62)	287 / 46,928 (61.16)	489 / 162,904 (30.02)
Other/Unknown	245 / 2,177,714 (1.13)	203 / 1,048,988 (1.94)	23 / 381,865 (0.6)	19 / 746,862 (0.25)
Ethnicity				
White	12,289 / 51,755,410 (2.37)	9,218 / 22,149,052 (4.16)	1,416 / 9,840,646 (1.44)	1,655 / 19,765,712 (0.84)
Asian	964 / 9,523,947 (1.01)	500 / 3,775,242 (1.32)	249 / 1,903,515 (1.31)	215 / 3,845,190 (0.56)
Black	242 / 2,813,798 (0.86)	143 / 1,438,408 (0.99)	66 / 662,912 (1)	33 / 712,478 (0.46)
Other/Mixed/Unknown	365 / 5,066,964 (0.72)	266 / 2,443,744 (1.09)	54 / 1,097,238 (0.49)	45 / 1,525,982 (0.29)

Index of Multiple Deprivation decile				
1	1,346 / 7,642,162 (1.76)	742 / 2,532,840 (2.93)	229 / 1,104,186 (2.07)	375 / 4,005,136 (0.94)
2	1,412 / 8,218,058 (1.72)	923 / 3,439,324 (2.68)	224 / 1,492,162 (1.5)	265 / 3,286,572 (0.81)
3	1,362 / 8,143,723 (1.67)	948 / 3,584,962 (2.64)	182 / 1,593,884 (1.14)	232 / 2,964,876 (0.78)
4	1,484 / 7,437,915 (2)	1,108 / 3,352,900 (3.3)	202 / 1,498,640 (1.35)	174 / 2,586,375 (0.67)
5	1,453 / 6,998,806 (2.08)	1,134 / 3,179,536 (3.57)	170 / 1,447,943 (1.17)	149 / 2,371,327 (0.63)
6	1,442 / 6,598,334 (2.19)	1,095 / 3,035,862 (3.61)	185 / 1,343,834 (1.38)	162 / 2,218,638 (0.73)
7	1,383 / 6,420,691 (2.15)	1,083 / 2,874,795 (3.77)	145 / 1,289,344 (1.12)	155 / 2,256,552 (0.69)
8	1,366 / 6,290,169 (2.17)	1,047 / 2,768,153 (3.78)	168 / 1,260,494 (1.33)	151 / 2,261,522 (0.67)
9	1,410 / 6,051,438 (2.33)	1,122 / 2,679,682 (4.19)	138 / 1,277,721 (1.08)	150 / 2,094,036 (0.72)
10	1,202 / 5,358,822 (2.24)	925 / 2,358,393 (3.92)	142 / 1,196,100 (1.19)	135 / 1,804,328 (0.75)
NHS England region				
East of England	1,867 / 7,696,944 (2.43)	1,586 / 4,694,240 (3.38)	191 / 1,818,968 (1.05)	90 / 1,183,736 (0.76)
London	1,518 / 14,484,721 (1.05)	1,127 / 7,683,234 (1.47)	303 / 4,019,058 (0.75)	88 / 2,782,428 (0.32)
Midlands	2,900 / 13,471,944 (2.15)	2,063 / 5,496,554 (3.75)	331 / 1,772,414 (1.87)	506 / 6,202,975 (0.82)
North East and Yorkshire	1,954 / 10,587,604 (1.85)	981 / 2,121,664 (4.62)	276 / 1,159,505 (2.38)	697 / 7,306,436 (0.95)
North West	1,475 / 8,495,294 (1.74)	811 / 1,790,338 (4.53)	265 / 1,241,257 (2.13)	399 / 5,463,698 (0.73)
South East	2,955 / 10,426,000 (2.83)	2,517 / 5,320,110 (4.73)	353 / 3,131,366 (1.13)	85 / 1,974,524 (0.43)
South West	1,191 / 3,997,611 (2.98)	1,042 / 2,700,304 (3.86)	66 / 361,742 (1.82)	83 / 935,566 (0.89)
Specimen date				
1 Nov–14 Nov	1,846 / 19,613,076 (0.94)	1,159 / 6,742,156 (1.72)	24 / 621,195 (0.39)	663 / 12,249,725 (0.54)

15 Nov–28 Nov	1,533 / 10,949,347 (1.4)	1,118 / 3,709,086 (3.01)	32 / 780,457 (0.41)	383 / 6,459,804 (0.59)
29 Nov–12 Dec	1,625 / 8,237,496 (1.97)	1,166 / 3,025,100 (3.85)	141 / 1,843,366 (0.76)	318 / 3,369,030 (0.94)
13 Dec–26 Dec	2,251 / 12,857,434 (1.75)	1,631 / 6,680,294 (2.44)	384 / 4,020,394 (0.96)	236 / 2,156,746 (1.09)
27 Dec–9 Jan	4,707 / 13,743,859 (3.42)	3,637 / 7,654,812 (4.75)	814 / 4,722,910 (1.72)	256 / 1,366,137 (1.87)
10 Jan–25 Jan	1,898 / 3,758,906 (5.05)	1,416 / 1,994,996 (7.1)	390 / 1,515,990 (2.57)	92 / 247,919 (3.71)

Table S2. Hazard ratios for SGTF / VOC across models.

	parameter	HR	95% LCL	95% UCL	Death type	Marker	Age term	IMD term	start date	end date	reg. cutoff (days)	strata	xvars	weighting
Death type														
	sgtf	1.61	1.42	1.84	c28	SGTF	S	S	2020-11-01		10	LTLA:date		cc
	sgtf	1.64	1.42	1.88	c28	SGTF	S	S	2020-11-01		10	LTLA:date		ipw
	sgtf	1.25	0.99	1.58	d07	SGTF	S	S	2020-11-01		10	LTLA:date		cc
	sgtf	1.57	1.18	2.08	d07	SGTF	S	S	2020-11-01		10	LTLA:date		ipw
	sgtf	1.40	1.20	1.62	d14	SGTF	S	S	2020-11-01		10	LTLA:date		cc
	sgtf	1.55	1.32	1.83	d14	SGTF	S	S	2020-11-01		10	LTLA:date		ipw
	sgtf	1.54	1.35	1.76	d21	SGTF	S	S	2020-11-01		10	LTLA:date		cc
	sgtf	1.66	1.44	1.92	d21	SGTF	S	S	2020-11-01		10	LTLA:date		ipw
	sgtf	1.58	1.40	1.79	d28	SGTF	S	S	2020-11-01		10	LTLA:date		cc
	sgtf	1.67	1.46	1.90	d28	SGTF	S	S	2020-11-01		10	LTLA:date		ipw
	sgtf	1.54	1.37	1.74	d60	SGTF	S	S	2020-11-01		10	LTLA:date		cc
	sgtf	1.64	1.43	1.87	d60	SGTF	S	S	2020-11-01		10	LTLA:date		ipw
	sgtf	1.54	1.37	1.74	dNA	SGTF	S	S	2020-11-01		10	LTLA:date		cc
	sgtf	1.63	1.43	1.87	dNA	SGTF	S	S	2020-11-01		10	LTLA:date		ipw
	sgtf	1.54	1.37	1.74	e60	SGTF	S	S	2020-11-01		10	LTLA:date		cc

	sgtf	1.64	1.43	1.87	e60	SGTF	S	S	2020-11-01		10	LTLA:date		ipw
Misclassification adjustment														
	p_voc	1.65	1.44	1.88	d28	pVOC	S	S	2020-09-01		10	LTLA:date		cc
	p_voc	1.72	1.49	1.99	d28	pVOC	S	S	2020-09-01		10	LTLA:date		ipw
	p_voc	1.63	1.44	1.86	d28	pVOC	S	S	2020-11-01		10	LTLA:date		cc
	p_voc	1.71	1.48	1.97	d28	pVOC	S	S	2020-11-01		10	LTLA:date		ipw
	p_voc	1.60	1.41	1.82	d60	pVOC	S	S	2020-11-01		10	LTLA:date		cc
	p_voc	1.69	1.46	1.95	d60	pVOC	S	S	2020-11-01		10	LTLA:date		ipw
Geographical and temporal stratification														
	sgtf	1.58	1.40	1.79	d28	SGTF	S	S	2020-11-01		10	LTLA:date		cc
	sgtf	1.67	1.46	1.90	d28	SGTF	S	S	2020-11-01		10	LTLA:date		ipw
	sgtf	1.52	1.36	1.69	d28	SGTF	S	S	2020-11-01		10	LTLA:week		cc
	sgtf	1.63	1.44	1.85	d28	SGTF	S	S	2020-11-01		10	LTLA:week		ipw
	sgtf	1.49	1.36	1.64	d28	SGTF	S	S	2020-11-01		10	NHSE:date		cc
	sgtf	1.47	1.28	1.68	d28	SGTF	S	S	2020-11-01		10	NHSE:date		ipw
	sgtf	1.50	1.37	1.65	d28	SGTF	S	S	2020-11-01		10	NHSE:week		cc
	sgtf	1.48	1.28	1.70	d28	SGTF	S	S	2020-11-01		10	NHSE:week		ipw
	sgtf	1.56	1.39	1.75	d28	SGTF	S	S	2020-11-01		10	UTLA:date		cc

	sgtf	1.56	1.37	1.78	d28	SGTF	S	S	2020-11-01		10	UTLA:date		ipw
	sgtf	1.51	1.36	1.67	d28	SGTF	S	S	2020-11-01		10	UTLA:week		cc
	sgtf	1.52	1.33	1.74	d28	SGTF	S	S	2020-11-01		10	UTLA:week		ipw
Age and IMD terms (linear vs. spline)														
	sgtf	1.58	1.40	1.79	d28	SGTF	L	L	2020-11-01		10	LTLA:date		cc
	sgtf	1.68	1.47	1.92	d28	SGTF	L	L	2020-11-01		10	LTLA:date		ipw
	sgtf	1.59	1.41	1.80	d28	SGTF	L	S	2020-11-01		10	LTLA:date		cc
	sgtf	1.69	1.47	1.93	d28	SGTF	L	S	2020-11-01		10	LTLA:date		ipw
	sgtf	1.57	1.39	1.78	d28	SGTF	S	L	2020-11-01		10	LTLA:date		cc
	sgtf	1.66	1.45	1.89	d28	SGTF	S	L	2020-11-01		10	LTLA:date		ipw
	sgtf	1.58	1.40	1.79	d28	SGTF	S	S	2020-11-01		10	LTLA:date		cc
	sgtf	1.67	1.46	1.90	d28	SGTF	S	S	2020-11-01		10	LTLA:date		ipw
By week since specimen														
	sgtf	1.26	1.00	1.59	d00-07	SGTF	S	S	2020-11-01		10	LTLA:date	sgtf_by_week	cc
	sgtf	1.56	1.17	2.08	d00-07	SGTF	S	S	2020-11-01		10	LTLA:date	sgtf_by_week	ipw
	sgtf	1.48	1.22	1.79	d08-14	SGTF	S	S	2020-11-01		10	LTLA:date	sgtf_by_week	cc
	sgtf	1.53	1.28	1.83	d08-14	SGTF	S	S	2020-11-01		10	LTLA:date	sgtf_by_week	ipw
	sgtf	2.16	1.63	2.85	d15-21	SGTF	S	S	2020-11-01		10	LTLA:date	sgtf_by_week	cc

	sgtf	2.18	1.63	2.91	d15-21	SGTF	S	S	2020-11-01		10	LTLA:date	sgtf_by_week	ipw
	sgtf	2.01	1.40	2.88	d22-28	SGTF	S	S	2020-11-01		10	LTLA:date	sgtf_by_week	cc
	sgtf	1.75	1.11	2.75	d22-28	SGTF	S	S	2020-11-01		10	LTLA:date	sgtf_by_week	ipw
Analysis start date														
	sgtf	1.55	1.37	1.75	d28	SGTF	S	S	2020-09-01		10	LTLA:date		cc
	sgtf	1.65	1.44	1.88	d28	SGTF	S	S	2020-09-01		10	LTLA:date		ipw
	sgtf	1.55	1.37	1.75	d28	SGTF	S	S	2020-10-01		10	LTLA:date		cc
	sgtf	1.65	1.44	1.88	d28	SGTF	S	S	2020-10-01		10	LTLA:date		ipw
	sgtf	1.58	1.40	1.79	d28	SGTF	S	S	2020-11-01		10	LTLA:date		cc
	sgtf	1.67	1.46	1.90	d28	SGTF	S	S	2020-11-01		10	LTLA:date		ipw
	sgtf	1.62	1.42	1.85	d28	SGTF	S	S	2020-12-01		10	LTLA:date		cc
	sgtf	1.69	1.46	1.95	d28	SGTF	S	S	2020-12-01		10	LTLA:date		ipw
	sgtf	1.69	1.39	2.04	d28	SGTF	S	S	2021-01-01		10	LTLA:date		cc
	sgtf	1.85	1.47	2.32	d28	SGTF	S	S	2021-01-01		10	LTLA:date		ipw
	sgtf	1.59	1.41	1.81	d28	SGTF	S	S	LTLA		10	LTLA:date		cc
	sgtf	1.68	1.47	1.93	d28	SGTF	S	S	LTLA		10	LTLA:date		ipw
Covariate interactions with time since positive test														
	sgtf	1.59	1.41	1.80	d28	SGTF	L	S	2020-11-01		10	LTLA:date	age:tstop	cc

	sgtf	1.68	1.47	1.93	d28	SGTF	L	S	2020-11-01		10	LTLA:date	age:tstop	ipw
	sgtf	1.58	1.40	1.79	d28	SGTF	S	S	2020-11-01		10	LTLA:date	sex:tstop	cc
	sgtf	1.67	1.46	1.91	d28	SGTF	S	S	2020-11-01		10	LTLA:date	sex:tstop	ipw
	sgtf	1.58	1.39	1.78	d28	SGTF	S	L	2020-11-01		10	LTLA:date	imd:tstop	cc
	sgtf	1.66	1.45	1.90	d28	SGTF	S	L	2020-11-01		10	LTLA:date	imd:tstop	ipw
	sgtf	1.58	1.40	1.79	d28	SGTF	S	S	2020-11-01		10	LTLA:date	eth:tstop	cc
	sgtf	1.67	1.46	1.90	d28	SGTF	S	S	2020-11-01		10	LTLA:date	eth:tstop	ipw
	sgtf	1.58	1.40	1.79	d28	SGTF	S	S	2020-11-01		10	LTLA:date	res:tstop	cc
	sgtf	1.67	1.46	1.91	d28	SGTF	S	S	2020-11-01		10	LTLA:date	res:tstop	ipw
No registration cutoff													
	sgtf	1.59	1.42	1.78	d28	SGTF	S	S	2020-11-01		0	LTLA:date		cc
	sgtf	1.61	1.42	1.83	d28	SGTF	S	S	2020-11-01		0	LTLA:date		ipw
Adjustment for, not stratification by, region and time													
	sgtf	1.50	1.37	1.65	d28	SGTF	S	S	2020-11-02	2020-01-24	10	NHSE:week		cc
	sgtf	1.48	1.28	1.71	d28	SGTF	S	S	2020-11-02	2020-01-24	10	NHSE:week		ipw
Subjects with full 28-day follow-up only													
	sgtf	1.46	1.22	1.74	d28	SGTF	S	S	2020-11-01	T - 38	0	LTLA:date		cc

	sgtf	1.52	1.28	1.79	d28	SGTF	S	S	2020-11-01	T - 38	0	LTLA:date		ipw
Asymptomatic screening indicator included as covariate														
	sgtf	1.58	1.39	1.79	d28	SGTF	S	S	2020-11-01		10	LTLA:date	asymptomatic	cc
	sgtf	1.66	1.45	1.90	d28	SGTF	S	S	2020-11-01		10	LTLA:date	asymptomatic	ipw
Alternative misclassification adjustment														
	p_voc	1.64	1.44	1.86	d28	pVOC2	S	S	2020-11-01		10	LTLA:date		cc
	p_voc	1.71	1.48	1.97	d28	pVOC2	S	S	2020-11-01		10	LTLA:date		ipw

Supplementary Figures

Fig. S1. Kaplan-Meier plots of survival within 60 days of positive test for SGTF versus non-SGTF by sex.

Fig. S2. Kaplan-Meier plots of survival within 60 days of positive test for SGTF versus non-SGTF by age group. Note that the Y axis differs for each panel.

Fig. S3. Kaplan-Meier plots of survival within 60 days of positive test for SGTF versus non-SGTF by residence. Note that the Y axis differs for each panel.

Fig. S4. Kaplan-Meier plots of survival within 60 days of positive test for SGTF versus non-SGTF by ethnicity.

Fig. S5. Kaplan-Meier plots of survival within 60 days of positive test for SGTF versus non-SGTF by Index of Multiple Deprivation (IMD) decile.

Fig. S6. Kaplan-Meier plots of survival within 60 days of positive test for SGTF versus non-SGTF by NHS region.

Fig. S7. Kaplan-Meier plots of survival within 60 days of positive test for SGTF versus non-SGTF by specimen date.

Fig. S8. Schoenfeld residuals for survival model by SGTF stratified by LTLA and specimen date . Model uses linear terms for age and IMD a 28-day followup using complete cases. Schoenfeld residual tests give $P = 0.031$ for SGTF; $P = 0.425$ for age; $P = 0.170$ for sex; $P = 0.603$ for IMD decile; $P = 0.410$ for ethnicity; $P = 0.728$ for residence type; and $P = 0.244$ globally.

Fig. S9. Misclassification model. For each NHS England region, we fit a beta-binomial model (purple, Modelled SGTF) to the observed SGTF frequencies among Pillar 2 tests (black, Observed SGTF), which estimates a constant proportion of "false positive" SGTF samples among non-VOC 202012/01 specimens (orange, Modelled non-VOC SGTF) and a logistically growing proportion of VOC 202012/01 specimens over time (blue, Modelled VOC). This allows us to model the conditional probability that a specimen with SGTF represents VOC 202012/01 (teal, P(VOC|SGTF)). For our misclassification survival analysis, p_{VOC} = 0 for non-SGTF specimens and p_{VOC} = P(VOC|SGTF) for SGTF specimens.

Fig. S10. Ct values for SGTF versus non-SGTF. The distribution of Ct values for (**a**) ORF1ab and (**b**) N gene targets among specimens collected between 1–25 January 2021.

Fig. S11. Q-Q plot assessing the fit of the final missingness model (Cauchit link).

Fig. S12. Comparison of the proportion of samples with S gene dropout in our Pillar 2 sample (testing data) compared to ONS (random sampling of the community).

References

1. Ministry of Housing & Communities & Local Government. English indices of deprivation 2019: technical report. https://www.gov.uk/government/publications/english-indices-of-deprivation-2019-technical-report (2019).

2. Cox, D. R. Regression Models and Life-Tables. *Journal of the Royal Statistical Society: Series B (Methodological)* **34**, 187–202 (1972).

3. Public Health England. *Investigation of novel SARS-COV-2 variant Variant of Concern 202012/01: Technical briefing 1*. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959438/Technical_Briefing_VOC_SH_NJL2_SH2.pdf (2020).

4. Keogh, R. H. *et al.* STRATOS guidance document on measurement error and misclassification of variables in observational epidemiology: Part 1-Basic theory and simple methods of adjustment. *Stat. Med.* **39**, 2197–2231 (2020).

5. Davies, N. G. *et al.* Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England. *bioRxiv* (2020) doi:10.1101/2020.12.24.20248822.

6. Department of Health and Social Care. NERVTAG paper on COVID-19 variant of concern B.1.1.7. https://www.gov.uk/government/publications/nervtag-paper-on-covid-19-variant-of-concern-b117 (2021).

7. COVID-19 confirmed deaths in England: report. https://www.gov.uk/government/publications/covid-19-reported-sars-cov-2-deaths-in-england/covid-19-confirmed-deaths-in-england-report.

8. Seaman, S. R. & White, I. R. Review of inverse probability weighting for dealing with missing data. *Stat. Methods Med. Res.* **22**, 278–295 (2013).

9. Levin, A. T. *et al.* Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. *Eur. J. Epidemiol.* **35**, 1123–1138 (2020).

10. Lumley, T. & Scott, A. Partial likelihood ratio tests for the Cox model under complex sampling. *Stat. Med.* **32**, 110–123 (2013).

11. Home - COG-UK Consortium. https://www.cogconsortium.uk/.

12. Imperial College London. Microreact - Open data visualization and sharing for genomic epidemiology. https://microreact.org/.